CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 178 enrolled
Drug / intervention
MR13A9 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04711603
NCT04711603Phase 3Completed
CompareCT.gov

A Phase III Clinical Study of MR13A9 in Hemodialysis Patients With Pruritus

Kissei Pharmaceutical Co., Ltd.·interventional·Posted Jan 15, 2021·Updated Sep 10, 2025

In Brief

A Phase 3 clinical trial evaluating MR13A9 and Placebo for Uremic Pruritus. Completed, enrolled 178 participants across 1 site.

Detailed Summary

Double-blind, Placebo-controlled study to confirm the superiority of MR13A9 to placebo, and followed by extension, open-label treatment to confirm long-term safety of MA13A9 in hemodialysis patients with pruritus.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUremic Pruritus
CountriesJapan
Collaborators--

Timeline

Phase 3CompletedFinished
202120222023202420252026
First PostedJan 15, 2021
Enrollment StartJan 16, 2021
Primary CompletionJan 25, 2022
Study CompletionSep 26, 2022
TodayJul 2, 2026
Enrollment to primary: 1.0 yearsPosted 5.5 years ago

Interventions

MR13A9drug

Intravenous administration

Placebodrug

Intravenous administration